Wanhuida Intellectual Property
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyAs an AstraZeneca patent survives a tenth invalidation challenge in China, Jianhui Li of Wanhuida Intellectual Property considers the implications for generic drug makers and the pharmaceutical industry -
Sponsored by Wanhuida Intellectual PropertyJicheng Yang of Wanhuida Intellectual Property considers whether a notable Beijing Intellectual Property Court decision signals a change to assessing inventive step in polymorph patents in China
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations involving active ingredients that are chemically reactive
-
Sponsored by Wanhuida Intellectual PropertyHonghui Hu of Wanhuida Intellectual Property examines how the Supreme People’s Court has clarified the patent scope of drug combination inventions in a patent linkage dispute, offering rare guidance on claim interpretation of pharmaceutical combinations
-
Sponsored by Wanhuida Intellectual PropertyZhigang Zhu, Xiaoyang Yang, and Feng Zheng of Wanhuida Intellectual Property outline the intellectual property-related challenges Chinese enterprises face in pursuing growth through overseas expansion, and explain the steps that can help navigate the complexities
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for the crystalline form of lemborexant and explains the implications for pharmaceutical patent strategies in China
